Non-small cell lung cancer | pharmaphorum

Sunday 8 February 2026

Non-small cell lung cancer

News

AstraZeneca

ASCO: AZ gets a practice-changing win in lung cancer

The question of whether adjuvant treatment with AstraZeneca’s Tagrisso can help patients with EGFR-positive non-small cell lung cancer live longer has finally been answere

News

AZ posts first-line combo data for lung cancer drug Tagrisso

AZ posts first-line combo data for lung cancer drug Tagrisso

AstraZeneca’s top-selling drug Tagrisso is already widely used on its own as a first-line treatment for EGFR-mutated lung cancer, but new data suggests there can be benefi

News

Merck suffers a setback in its TIGIT programme

Merck suffers a setback in its TIGIT programme

Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.

News

AZ cancer drugs chalk up wins in early-stage lung cancer

AZ cancer drugs chalk up wins in early-stage lung cancer

Tagrisso and Imfinzi show benefit as neoadjuvant and adjuvant therapy for patients with NSLC.

News

Merck drops last phase 3 Keytruda trial in prostate cancer

Merck drops last phase 3 Keytruda trial in prostate cancer

KEYNOTE-641 showed no benefit when added to Xtandi for castration-resistant prostate cancer.

News

NICE okays neoadjuvant Opdivo in lung cancer

NICE okays neoadjuvant Opdivo in lung cancer

BMS' checkpoint inhibitor is first to be given a green light for use before surgery in NSCLC.